CoreValve

CoreValve
Name	CoreValve
Type	Transcatheter aortic valve replacement device
Inventor	Edwards Lifesciences competitors context
Manufacturer	Medtronic
Introduced	2005
Website	Medtronic

CoreValve is a self-expanding transcatheter aortic valve replacement (TAVR) prosthesis developed for treatment of severe aortic stenosis in patients at elevated surgical risk. The device was created to enable percutaneous access to the aortic valve using catheter-based techniques pioneered in interventional cardiology and cardiothoracic surgery. CoreValve has been evaluated in large randomized trials, registry studies, and postmarket surveillance involving multiple tertiary centers and national cardiovascular societies.

History

The development trajectory of CoreValve intersects with advances made by leaders in interventional cardiology such as Alain Cribier and industry innovators including Edwards Lifesciences and Medtronic. Early clinical adoption followed feasibility work in Europe and investigational device trials supported by collaborative networks involving Massachusetts General Hospital and Cleveland Clinic investigators. Pivotal randomized trials compared the device against surgical aortic valve replacement at high and intermediate risk, with regulatory interactions involving agencies like the Food and Drug Administration and the European Medicines Agency. Professional society guidance from entities such as the American College of Cardiology and the Society of Thoracic Surgeons subsequently incorporated TAVR into care pathways. Commercial milestones included mergers and acquisitions affecting device strategy among multinational corporations headquartered in Ireland and Minnesota.

Device Design and Components

The prosthesis features a nitinol self-expanding frame combined with bovine pericardial leaflets manufactured and assembled under standards used by manufacturers including Medtronic and subcontractors in medical device hubs such as Boston and Shanghai. The frame geometry is designed for supra-annular leaflet placement to optimize effective orifice area, drawing on engineering principles employed by structural heart device teams at Stanford University and Imperial College London. Implant delivery uses a catheter-based sheath compatible with transfemoral, trans-subclavian, and transapical access routes adopted by interventional teams at centers like Johns Hopkins Hospital and Mount Sinai Hospital. Ancillary components include radiopaque markers for fluoroscopic guidance, sealing skirts to mitigate paravalvular leak—concepts refined in device iteration cycles influenced by research groups at Karolinska Institutet and Ghent University Hospital.

Indications and Clinical Use

Regulatory indications have targeted symptomatic severe aortic stenosis in patients deemed at high or prohibitive surgical risk by multidisciplinary heart teams featuring clinicians from American Heart Association, European Society of Cardiology, and national cardiac surgery organizations. Clinical algorithms incorporate multimodality imaging from experts at Mayo Clinic and Royal Brompton Hospital, including echocardiography, computed tomography angiography analyzed with software developed by vendors like Philips and Siemens Healthineers. Patient selection also references scores and registries such as the STS risk score and large-scale databases managed by consortia including the Transcatheter Valve Therapy Registry. Off-label and investigational use has been explored in bicuspid aortic valve cohorts studied at referral centers like University of Toronto and Cleveland Clinic.

Implantation Procedure

The procedure is performed in hybrid operating rooms staffed by multidisciplinary teams combining expertise from interventional cardiology and cardiac surgery disciplines, with anesthetic strategies informed by guidelines from the American Society of Anesthesiologists. Vascular access is commonly transfemoral via percutaneous puncture guided by ultrasound and fluoroscopy used in catheterization laboratories at institutions such as Guy's and St Thomas' NHS Foundation Trust and Charité – Universitätsmedizin Berlin. Valve deployment uses controlled retraction of the delivery catheter to permit self-expansion into the native annulus, with positioning confirmed by angiography and transesophageal echocardiography techniques refined at Cleveland Clinic and Mayo Clinic. Bail-out strategies include rapid pacing protocols derived from electrophysiology groups at University of Pennsylvania and conversion to open surgery facilitated by cardiac surgical teams at tertiary centers like Massachusetts General Hospital.

Clinical Outcomes and Complications

Randomized trials and registries reported outcome measures including all-cause mortality, stroke, rehospitalization, and valve hemodynamics with follow-up protocols aligned with endpoints committees from trials run by organizations such as Duke Clinical Research Institute and University College London. Compared with surgical aortic valve replacement in high-risk cohorts, studies demonstrated comparable or superior short-term survival and faster recovery recorded in trials coordinated by teams at University of Leipzig and Columbia University. Complications reported include paravalvular regurgitation, conduction disturbances requiring permanent pacemaker implantation—an issue investigated by electrophysiology groups at Cleveland Clinic—vascular access complications, and rare events such as prosthetic valve endocarditis studied by infectious disease units at Johns Hopkins Hospital. Long-term durability and structural valve degeneration have been subjects of longitudinal analyses in registries maintained by the European Association of Percutaneous Cardiovascular Interventions and academic centers at Imperial College London.

Regulatory Approval and Availability

Initial CE mark approval in Europe enabled early commercial use, followed by regulatory review and approval processes with the Food and Drug Administration for specific patient risk cohorts. Post-approval surveillance and device labeling were influenced by health technology assessment bodies including NICE in the United Kingdom and reimbursement discussions with national payers such as Medicare in the United States. Global availability expanded through distribution networks managed by multinational medical device corporations headquartered in Dublin and regional partners across Asia, Latin America, and Africa, with training programs delivered at academic centers including Mayo Clinic and Johns Hopkins Hospital.

Category:Cardiac valve prostheses